Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: Adverse events and other reasons for discontinuation of treatment

Scandinavian Journal of Rheumatology

Volumn 37, Issue 1, 2008, Pages 6-12

  Levalampi T ^a   Korpela, M ^b   Vuolteenaho, K ^a   Moilanen, E ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; SPONDYLARTHRITIS; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 38149092440     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701633337     Document Type: Article

References (32)

1. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
4. Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthritides. Scand J Rheumatol 2005;34:178-90.
5. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
6. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii30-3.
7. Wendling D, Materne GE, Michel F, Lohse A, Lehuede G, Toussirot E, et al. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 2005;72:309-12.
8. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2005;118:515-20.
9. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
10. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76.
11. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor-{alpha} blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford).
12. Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 2004;31:1912-17.
13. [Working group set by Finnish Medical Society Duodecim and Finnish Society for Rheumatology, Helsinki, Finland. Rheumatoid arthritis Current Care Guideline (update June 2003). Finland Medical Society Duodecim], in Finnish (www.kaypahoito.fi).
14. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
15. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
16. Carmona L, Gomez-Reino JJ; BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72.
17. Nordstrom DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg S, et al. Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int 2005:1-8.
18. Mutru O, Laakso M, Isomaki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985;290:1797-9.
19. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
20. Capell HA. Disease modifying antirheumatic drugs: long-term safety issues. J Rheumatol Suppl 2001;62:10-15.
21. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
22. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
23. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
24. World Health Organization, Tuberculosis country profile/Finland (www.who.int/globalatlas/dataQuery/default.asp).
25. World Health Organization, Tuberculosis: infection and transmission (www.who.int/mediacentre/factsheets/fs104/en/index.html#global).
26. Konttinen L, Honkanen V, Uotila T, Pollanen J, Waahtera M, Romu M, et al. Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 2006;26:916-22.
27. Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 2003;139:W-63.
28. Favalli EG, Varenna M, Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheumatol 2005;23:247-50.
29. Montane E, Salles M, Barriocanal A, Riera E, Costa J, Tena X. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol 2007;26:1527-9.
30. Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64:1519-20.
31. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 2006;295:2275-85.
32. Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004;63:1538-43.